Page last updated: 2024-08-22

lutetium and taxane

lutetium has been researched along with taxane in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Barber, TW; Baum, RP; Billah, B; Kulkarni, HR; Niepsch, K; Singh, A	1
Antonarakis, ES; Denmeade, SR; Eisenberger, MA; Eshleman, JR; Isaacsson Velho, P; Luo, J; Paller, CJ; Piana, D; Pomper, MG; Riel, S; Rowe, SP	1
Jacene, H; Ravi, P; Shah, H; Sonpavde, G	1
Bal, C; Sahoo, RK; Satapathy, S	1

Reviews

2 review(s) available for lutetium and taxane

Article	Year
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert review of anticancer therapy, 2022, Volume: 22, Issue:11 Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2022
[ Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023, Volume: 64, Issue:8 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2023

Other Studies

2 other study(ies) available for lutetium and taxane

Article	Year
Clinical Outcomes of Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, Volume: 60, Issue:7 Topics: Aged; Aged, 80 and over; Bridged-Ring Compounds; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Safety; Taxoids; Time Factors; Treatment Outcome	2019
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. The Prostate, 2019, Volume: 79, Issue:14 Topics: Aged; Aged, 80 and over; Antigens, Surface; Bridged-Ring Compounds; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; RNA, Messenger; Taxoids; Treatment Outcome	2019

Article

Year

Clinical Outcomes of

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, Volume: 60, Issue:7

Topics: Aged; Aged, 80 and over; Bridged-Ring Compounds; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Safety; Taxoids; Time Factors; Treatment Outcome

2019

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.

The Prostate, 2019, Volume: 79, Issue:14

Topics: Aged; Aged, 80 and over; Antigens, Surface; Bridged-Ring Compounds; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; RNA, Messenger; Taxoids; Treatment Outcome

2019